Expensive Pharmaceuticals for Targeted Diseases

In her latest paper, titled "The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine," the author examines the economic challenges associated with targeted drugs that offer cures. The $850,000 price tag for Luxturna, a gene therapy, is often criticized as evidence of private profiteering from publicly funded scientific research.

However, the author argues that this perspective overlooks crucial economic realities. Pharmaceutical companies operate in a hit-driven industry where most projects fail; therefore, the successful few must generate profitability far exceeding their direct costs to secure investment. Precision medicine exacerbates these financial pressures through two main issues: the steep upfront cost of one-time cures and the shrinking market resulting from targeting drugs to smaller patient groups.

These challenges create financing problems and require higher rewards to sustain innovation. The paper suggests a policy toolkit to address these concerns, including spreading payments over time, bundling diagnostics with drugs, and simplifying regulation to reduce development expenses. The ultimate goal is to maintain innovation while increasing patient access to these life-changing treatments.